达雷妥尤单抗注射液的药物利用评价标准的建立与应用OA

OBJECTIVE:To establish drug use evaluation(DUE)criteria for daratumumab injection,evaluate and analyze the clinical application,so as to provide references for rational application.METHODS:Based on domestic and international drug dispensatories for daratumumab injection,and with reference to relevant clinical guidelines,literature,diagnostic and treatment specifications,the DUE criteria comprising multiple dimensions including medication indications,administration procedures and treatment outcomes was developed by using the Delphi method.Evaluation on medication rationality was performed on inpatients from Jan.2022 to Jun.2025 in a large gradeⅢ,level A hospital in Xinjiang.RESULTS:The finally established DUE criteria for daratumumab injection comprised 4 primary indicators and 14 secondary indicators.A total of 1 012 eligible cases were enrolled,949 cases(93.77％)met the indication criteria,of which 851 cases(84.09％)completely met the medication indications;63 cases(6.23％)involved off-label drug use.There were 85 cases(8.40％)of adverse drug reactions related to medication,all rated as"possibly"in correlation assessment,with most outcomes being cured or improved.Symptom relief was explicitly documented in 677 cases(66.90％),while 335 cases(33.10％)lacked detailed descriptions of symptom improvement.CONCLUSIONS:The DUE criteria established for daratumumab injection demonstrate good scientificity and practical applicability.Issues identified in the clinical application of daratumumab injection can serve as key targets for proactive interventions by pharmaceutical departments,thereby guiding rational clinical medication and ensuring patient medication safety.